Physician profile
Seth B Stuart
NPI 1902578685
$4,643.16
in general payments reported to CMS, 2019-2025
30 companies · $1,303 in 2025
The $1,303 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $166 · 2022: $497 · 2023: $1,160 · 2024: $1,517 · 2025: $1,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,151 · Travel and Lodging: $812 · Education: $17.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,150.82 |
| Travel and Lodging | $811.63 |
| Education | $17.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,370.54 | 2022-2025 | Urolift, Barrigel |
| Sumitomo Pharma America, INC. | $663.01 | 2023-2025 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $464.53 | 2021-2025 | |
| Janssen Biotech, INC. | $442.74 | 2024-2025 | Erleada, Akeega, Balversa |
| Abbvie INC. | $415.36 | 2021-2025 | |
| Dendreon Pharmaceuticals LLC | $262.79 | 2023-2025 | Provenge |
| Astellas Pharma US INC | $142.92 | 2022-2025 | Xtandi, Myrbetriq |
| Verity Pharmaceuticals INC. | $140.92 | 2023-2025 | Trelstar |
| Merck Sharp & Dohme LLC | $106.81 | 2021-2025 | Keytruda |
| Myriad Genetic Laboratories, INC. | $91.74 | 2024 | Prolaris |
| Novartis Pharmaceuticals Corporation | $58.49 | 2025 | |
| Coloplast Corp | $46.25 | 2021-2024 | Speedicath |
| Accord Healthcare, INC. | $43.89 | 2024 | |
| Progenics Pharmaceuticals, INC. | $39.40 | 2023-2024 | Pylarify |
| Urogen Pharma, INC. | $39.06 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $37.01 | 2022 | |
| Pfizer INC. | $36.43 | 2024 | |
| Hollister Incorporated | $30.18 | 2022 | |
| Inspire Medical Systems, INC. | $25.52 | 2024 | Inspire |
| Allergan, INC. | $25.32 | 2021 | |
| Boston Scientific Corporation | $24.43 | 2023 | Spaceoar Vue System - 10ml |
| Endo Pharmaceuticals INC. | $17.88 | 2022 | |
| Coopersurgical, INC. | $17.56 | 2025 | Onetrac Lx |
| Medtronic, INC. | $16.57 | 2025 | Interstim |
| Mission Pharmacal Company | $15.72 | 2022 | |
| Ferring Pharmaceuticals INC. | $15.43 | 2025 | Adstiladrin |
| Angiodynamics, INC. | $13.81 | 2024 | Nanoknife |
| Antares Pharma, INC. | $13.46 | 2023 | Xyosted, Tlando, Nocdurna |
| Urovant Sciences INC | $12.92 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Stuart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.